Supplemental material
Emerging Microbes & Infections
Volume 7, 2018 - Issue 1
Related Research Data
Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.
Source:
Elsevier BV
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
Source:
Springer Science and Business Media LLC
Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection
Source:
Springer Science and Business Media LLC
Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge
Source:
American Society for Microbiology
Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity
Source:
The American Association of Immunologists
VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain
Source:
American Association for the Advancement of Science (AAAS)
Ebola virus: from discovery to vaccine
Source:
Springer Science and Business Media LLC
Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice
Source:
Elsevier BV
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates
Source:
Springer Science and Business Media LLC
Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs.
Source:
Elsevier BV
Enhanced Protection against Ebola Virus Mediated by an Improved Adenovirus-Based Vaccine
Source:
Public Library of Science (PLoS)
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.
Source:
Springer Science and Business Media LLC
Ebola virus epidemiology, transmission, and evolution during seven months in Sierra Leone
Source:
Elsevier BV
An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates
Source:
Oxford University Press (OUP)
Epidemiology of adenovirus type 5 neutralizing antibodies in healthy people and AIDS patients in Guangzhou, southern China
Source:
Elsevier BV
Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice
Source:
Oxford University Press (OUP)
A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection.
Source:
American Chemical Society (ACS)
Induction of Humoral and CD8+ T Cell Responses Are Required for Protection against Lethal Ebola Virus Infection
Source:
The American Association of Immunologists
Emergence of Zaire Ebola Virus Disease in Guinea
Source:
Massachusetts Medical Society
An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques
Source:
Figshare
The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2.
Source:
Elsevier BV
Ebola virus-like particles protect from lethal Ebola virus infection
Source:
Proceedings of the National Academy of Sciences
A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge
Source:
Proceedings of the National Academy of Sciences
Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice
Source:
Informa UK Limited
Prevalence of Ad14 and 55-neutralizing antibodies
Source:
Informa UK Limited
Linking provided by
